Percutaneous implantation of the first repositionable aortic valve prosthesis in a patient with severe aortic stenosis

Department of Cardiology, HELIOS Heart Center Siegburg, Siegburg, Germany.
Catheterization and Cardiovascular Interventions (Impact Factor: 2.4). 04/2008; 71(5):579-84. DOI: 10.1002/ccd.21470
Source: PubMed

ABSTRACT Percutaneous aortic valve replacement is a new less-invasive alternative for high-risk surgical candidates with aortic stenosis. However, the clinical experience is still limited, and the currently available 'first-generation devices' revealed technical shortcomings, such as lack of repositionability and presence of paravalvular leakages. We report the first-in-man experience with the new self-expanding Lotus Valve prosthesis composed of a nitinol frame with implemented bovine pericardial leaflets which is designed to address these issues, being repositionable and covered by a flexible membrane to seal paravalvular gaps. We implanted this prosthesis in a 93-year old patient presenting with severe symptomatic aortic stenosis (valve area: 0.6 cm(2)). Surgical valve replacement had been declined due to comorbidities.
We used a retrograde approach for insertion of the 21-French Lotus catheter loaded with the valve prosthesis via surgical cut-down to the external iliac artery. Positioning of the valve was guided by transesophageal echo and supra-aortic angiograms. The prosthesis was successfully inserted and deployed within the calcified native valve. Echocardiography immediately after device deployment showed a significant reduction of the transaortic mean pressure gradient (32 to 9 mmHg; final valve area 1.7 cm(2)) without evidence of residual aortic regurgitation. The postprocedural clinical status improved from NYHA-IV to NYHA-II. These results remained unchanged up to the 3 month follow-up.
Successful percutaneous aortic valve replacement can be performed using the new self-expanding and repositionable Lotus valve for treatment of high-risk patients with aortic valve stenosis. Further studies are mandatory to assess device safety and efficacy in larger patient populations.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Transcatheter aortic valve implantation (TAVI) has become the preferred treatment option for patients with symptomatic severe aortic stenosis who are inoperable or at high risk for surgical aortic valve replacement. TAVI has shown a clear mortality benefit compared to conservative treatment in inoperable patients, and is at least non-inferior to surgical aortic valve replacement in high-risk operable patients. Through improvements in the field of imaging, refinement in valve technologies, increasing operator and team experience and continuous valuable research, TAVI has developed rapidly in the past years and is expected to further boost in the near future. In this review, we discuss the technical and procedural aspects of TAVI, the acute and late outcomes, and highlight the current expectations and potential future development of this rapidly evolving technology.
    Expert Review of Cardiovascular Therapy 07/2014; DOI:10.1586/14779072.2014.929942
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transcatheter aortic valve implantation (TAVI) is nowadays an accepted method of treatment for the patients with symptomatic severe aortic stenosis who are inoperable or at very high risk of classic surgical aortic valve replacement. The Lotus Valve System is a new generation TAVI device composed of self-expanding stent prosthesis with implemented bovine pericardial leaflets, which is designed to facilitate repositiong, resheating and retrieval even in fully expanded and functioning position before the final release. In addition the Lotus valve is surrounded by flexible membrane to seal paravalvular gaps between the prosthesis and native valve. We present the first polish experiences with the Lotus Valve System. Due to its unique features the Lotus valve may improve the prognosis in patients with inoperable or high risk critical aortic stenosis.
    Kardiologia polska 10/2014; DOI:10.5603/KP.a2014.0191 · 0.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Assessment of elderly patients with severe aortic stenosis and decisions in terms of management strategy (conservative with or without balloon aortic valvuloplasty, transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement) are complex and warrant a multidisciplinary approach involving collaboration between experienced cardiac surgeons, interventional cardiologists, cardiac imaging specialists, anaesthesiologists, geriatricians and a specialised nursing staff. Patient history, comorbid conditions, perioperative risk stratification as well as anatomical and procedural considerations require careful review on an individual, case-by-case basis and have a major impact on treatment allocation. The aims of this article are to provide insights into the fundamental role of appropriate patient screening and selection, and to review the nature, management and prevention of the most important procedural complications associated with the TAVI procedure.
    Heart (British Cardiac Society) 11/2012; 98 Suppl 4:iv52-64. DOI:10.1136/heartjnl-2012-302403 · 6.02 Impact Factor